Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 19/20 | 1.00 |
| ▸ | HTR1A | P08908 | 18/20 | 1.00 |
| ▸ | HTR1D | P28221 | 16/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | HTR2C | P28335 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8628236 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907348 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907353 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL17402421 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL8624139 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL17402426 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907322 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL8631086 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| SCHEMBL14907325 | 1.00 | HTR1B (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 | |
| Hydrochloric Acid SCHEMBL21523192 | 0.99 | MAPT (1.00) | HTR1BHTR1AHTR1DMAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| EP-4536236-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | University of Utah Research Foundation (US) | 2025-04-16 | — | — | EP | claimed |
| WO-2024173715-A1 | ANTIFUNGAL COMPOSITIONS AND METHODS OF USE THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-08-22 | — | — | WO | claimed |
| WO-2023239747-A2 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2023-12-14 | — | — | WO | claimed |
| US-20230121771-A1 | A PHARMACEUTICAL COMBINATION OF AN ARTEMISININ COMPOUND, 5-AMINOLEVULINIC ACID OR METHYL-5-AMINOLEVULINIC ACID AND A CHEMOTHERAPEUTIC AGENT | JLP HEALTH GMBH (AT) | 2023-04-20 | — | — | US | claimed |
| CN-114786661-A | Pharmaceutical combination of an artemisinin compound, 5-aminolevulinic acid or methyl-5-aminolevulinic acid and a chemotherapeutic agent | JLP健康有限公司 | 2022-07-22 | — | — | CN | claimed |
| EP-3989961-A1 | A PHARMACEUTICAL COMBINATION OF AN ARTEMISININ COMPOUND, 5-AMINOLEVULINIC ACID OR METHYL-5-AMINOLEVULINIC ACID AND A CHEMOTHERAPEUTIC AGENT | JLP Health GmbH (AT) | 2022-05-04 | — | — | EP | claimed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | claimed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | claimed |
| EP-4748838-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-3704090-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CITY OF HOPE (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | UNIV OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | US | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20020173511-A1 | Serotonergic compositions and methods for treatment of mild cognitive impairment | WURTMAN RICHARD J (US) | 2002-11-21 | — | — | US | disclosed |
| WO-2002038142-A2 | SEROTONERGIC COMPOSITIONS AND METHODS FOR TREATMENT OF MILD COGNITIVE IMPAIRMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2002-05-16 | — | — | WO | disclosed |
| EP-0666847-B1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMA (CA) | 1998-06-17 | — | — | EP | disclosed |
| US-5496957-A | 5-HYDOXYTRYPTAMINE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 1996-03-05 | — | — | US | disclosed |
| EP-0666847-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | Allelix Biopharmaceuticals Inc. (CA) | 1995-08-16 | — | — | EP | disclosed |
| WO-1995006638-A1 | TRYPTAMINE ANALOGS WITH 5-HT1D SELECTIVITY | ALLELIX BIOPHARMACEUTICALS INC. (CA) | 1995-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637510-B2 | Oncolytic virus compositions and methods for the treatment of cancer | CD47, IGLV6-57, STING1 | HTR1B 4202/4885HTR1A 4578/4885HTR1D 4636/4885 |
| US-20260137707-A1 | METHODS OF MODULATING ATXN2 EXPRESSION | ATXN2, ATXN2L, ATP6V1B2 | HTR1B 1307/4885HTR1A 2508/4885HTR1D 2659/4885 |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | HTR1B 3339/4885HTR1A 2444/4885HTR1D 3340/4885 |
| US-20230121771-A1 | A PHARMACEUTICAL COMBINATION OF AN ARTEMISININ COMPOUND, 5-AMINOLEVULINIC ACID OR METHYL-5-AMINOLEVULINIC ACID AND A CHEMOTHERAPEUTIC AGENT | DHPS, GLS2, THPO | HTR1B 1056/4885HTR1A 1164/4885HTR1D 1974/4885 |
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | HTR1B 4055/4885HTR1A 2572/4885HTR1D 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.